Evidence map›Paper›PMID 35481737›Full record

ArticleTurkish journal of ophthalmology2022

Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic Therapy

Özge Yanık, Figen Batıoğlu, Nilüfer Yalçındağ, Sibel Demirel, Emin Özmert

Abstract readCase Reports
In one paragraph

Article in Turkish journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Özge YanıkAnkara University Faculty of Medicine, Department of Ophthalmology, Ankara, TurkeyORCID 0000-0002-1822-8703
Figen BatıoğluAnkara University Faculty of Medicine, Department of Ophthalmology, Ankara, TurkeyORCID 0000-0002-5834-7512
Nilüfer YalçındağAnkara University Faculty of Medicine, Department of Ophthalmology, Ankara, TurkeyORCID 0000-0002-8963-5146
Sibel DemirelAnkara University Faculty of Medicine, Department of Ophthalmology, Ankara, TurkeyORCID 0000-0002-6430-6565
Emin ÖzmertAnkara University Faculty of Medicine, Department of Ophthalmology, Ankara, TurkeyORCID 0000-0001-7561-5075

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this case report is to describe a case of atypical central serous chorioretinopathy (CSCR) definitively diagnosed after 8 years. A 44-year-old woman presented with reduced visual acuity in her left eye. Her visual acuity was light perception with projection in the right eye and 0.15 in the left. She described a similar decline in vision in her right eye 8 years ago. At that time, she had exudative retinal detachment and was treated with systemic immunosuppressive therapy for a presumed diagnosis of Vogt-Koyanagi-Harada disease. Despite resolution of the exudative retinal detachment, macular scarring developed. Eight years later, she developed inferior exudative retinal detachment in the left eye. A diagnosis of atypical CSCR was made with the help of multimodal imaging and her left eye was successfully treated with eplerenone and half-fluence photodynamic therapy (hf-PDT). In conclusion, early diagnosis and treatment of atypical CSCR may prevent subretinal fibrosis formation and permanent vision loss. Hf-PDT and eplerenone are successful treatment options for atypical CSCR.

Indexed as

Central Serous ChorioretinopathyPhotochemotherapyRetinal DetachmentUveomeningoencephalitic SyndromeChildEplerenoneFemaleHumansEplerenoneAtypical central serous chorioretinopathyeplerenoneindocyanine green angiographyphotodynamic therapy

Identifiers

PMID35481737
PMCPMC9069095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.